MCK vs. UTHR: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at MCK and UTHR, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | MCK | UTHR |
|---|---|---|
| Company Name | McKesson Corporation | United Therapeutics Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 82.49 billion USD | 14.01 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | November 10, 1994 | June 17, 1999 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of MCK and UTHR by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | MCK | UTHR |
|---|---|---|
| 5-Day Price Return | -0.01% | 3.44% |
| 13-Week Price Return | -3.54% | -0.35% |
| 26-Week Price Return | 10.57% | -12.45% |
| 52-Week Price Return | 20.36% | -7.21% |
| Month-to-Date Return | -4.38% | 12.75% |
| Year-to-Date Return | 16.36% | -12.22% |
| 10-Day Avg. Volume | 1.19M | 0.89M |
| 3-Month Avg. Volume | 0.93M | 0.57M |
| 3-Month Volatility | 21.82% | 40.95% |
| Beta | 0.51 | 0.62 |
Profitability
Return on Equity (TTM)
MCK
39.43%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
MCK’s Return on Equity of 39.43% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
UTHR
18.73%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, UTHR’s Return on Equity of 18.73% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
MCK
0.92%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
Falling into the lower quartile for the Health Care Providers & Services industry, MCK’s Net Profit Margin of 0.92% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
UTHR
40.36%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 40.36% places UTHR in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
MCK
1.23%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
MCK’s Operating Profit Margin of 1.23% is in the lower quartile for the Health Care Providers & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
UTHR
47.05%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 47.05% places UTHR in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | MCK | UTHR |
|---|---|---|
| Return on Equity (TTM) | 39.43% | 18.73% |
| Return on Assets (TTM) | 4.54% | 16.48% |
| Net Profit Margin (TTM) | 0.92% | 40.36% |
| Operating Profit Margin (TTM) | 1.23% | 47.05% |
| Gross Profit Margin (TTM) | 3.59% | 88.98% |
Financial Strength
Current Ratio (MRQ)
MCK
0.90
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
MCK’s Current Ratio of 0.90 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
UTHR
7.26
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
UTHR’s Current Ratio of 7.26 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
MCK
1.29
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
MCK’s leverage is in the upper quartile of the Health Care Providers & Services industry, with a Debt-to-Equity Ratio of 1.29. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
UTHR
0.00
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
UTHR’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
MCK
17.45
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
With an Interest Coverage Ratio of 17.45, MCK demonstrates a superior capacity to service its debt, placing it well above the typical range for the Health Care Providers & Services industry. This stems from either robust earnings or a conservative debt load.
UTHR
42.15
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
UTHR’s Interest Coverage Ratio of 42.15 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | MCK | UTHR |
|---|---|---|
| Current Ratio (MRQ) | 0.90 | 7.26 |
| Quick Ratio (MRQ) | 0.51 | 6.94 |
| Debt-to-Equity Ratio (MRQ) | 1.29 | 0.00 |
| Interest Coverage Ratio (TTM) | 17.45 | 42.15 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
MCK
0.42%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
MCK’s Dividend Yield of 0.42% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
UTHR
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
MCK
10.47%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
MCK’s Dividend Payout Ratio of 10.47% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
UTHR
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
UTHR has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | MCK | UTHR |
|---|---|---|
| Dividend Yield (TTM) | 0.42% | 0.00% |
| Dividend Payout Ratio (TTM) | 10.47% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
MCK
25.15
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
MCK’s P/E Ratio of 25.15 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
UTHR
11.06
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Biotechnology industry, UTHR’s P/E Ratio of 11.06 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
MCK
0.23
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
In the lower quartile for the Health Care Providers & Services industry, MCK’s P/S Ratio of 0.23 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
UTHR
4.47
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, UTHR’s P/S Ratio of 4.47 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
MCK
4.06
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
MCK’s P/B Ratio of 4.06 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
UTHR
1.81
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
UTHR’s P/B Ratio of 1.81 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | MCK | UTHR |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 25.15 | 11.06 |
| Price-to-Sales Ratio (TTM) | 0.23 | 4.47 |
| Price-to-Book Ratio (MRQ) | 4.06 | 1.81 |
| Price-to-Free Cash Flow Ratio (TTM) | 8.88 | 12.83 |